Location of Repository

Drugs for neglected diseases: a failure of the market and a public health failure?

By P Trouiller, E Torreele, P Olliaro, N J J White, S Foster, D Wirth and B Pécoul

Abstract

Infectious diseases cause the suffering of hundreds of millions of people, especially in tropical and subtropical areas. Effective, affordable and easy-to-use medicines to fight these diseases are nearly absent. Although science and technology are sufficiently advanced to provide the necessary medicines, very few new drugs are being developed. However, drug discovery is not the major bottleneck. Today's R&D-based pharmaceutical industry is reluctant to invest in the development of drugs to treat the major diseases of the poor, because return on investment cannot be guaranteed. With national and international politics supporting a free market-based world order, financial opportunities rather than global health needs guide the direction of new drug development. Can we accept that the dearth of effective drugs for diseases that mainly affect the poor is simply the sad but inevitable consequence of a global market economy? Or is it a massive public health failure, and a failure to direct economic development for the benefit of society? An urgent reorientation of priorities in drug development and health policy is needed. The pharmaceutical industry must contribute to this effort, but national and international policies need to direct the global economy to address the true health needs of society. This requires political will, a strong commitment to prioritize health considerations over economic interests, and the enforcement of regulations and other mechanisms to stimulate essential drug development. New and creative strategies involving both the public and the private sector are needed to ensure that affordable medicines for today's neglected diseases are developed. Priority action areas include advocating an essential medicines R&D agenda, capacity-building in and technology transfer to developing countries, elaborating an adapted legal and regulatory framework, prioritizing funding for essential drug development and securing availability, accessibility, distribution and rational use of these drugs

Publisher: Wiley-Blackwell
Year: 2001
OAI identifier: oai:fieldresearch.msf.org:10144/28439
Provided by: MSF Field Research
Journal:

Suggested articles

Preview

Citations

  1. (1999). Access to essential drugs in poor countries. A lost battle?
  2. (2000). AIDS: patent rights versus patient’s rights.
  3. (1997). Call for more reliable costs data on clinical trials.
  4. (1998). Can patents deter innovation? The anticommons in biomedical research.
  5. (2000). Coghlan A
  6. (1998). Dilemmas in drug development for tropical diseases, experiences with praziquantel.
  7. (1999). Drug development output from 1975 to 1996: what proportion for tropical diseases?
  8. (2001). Drugs for neglected diseases 950 ª
  9. (2001). Drugs for neglected diseases ª
  10. (2001). Global Competitiveness in Pharmaceuticals, a European Perspective.
  11. (1999). Global Forum for Health Research
  12. (1999). Global treatment and access to medicines: AIDS drugs in Thailand.
  13. (1999). Globalization and Access to Drugs. Perspectives on the WTO/Trips Agreement. WHO/DAP/ 98.9. World Health Organization,
  14. (1997). Globalization and harmonization of regulatory issues: the WHO perspective of developing countries’ needs and perspectives.
  15. (1999). Helping the world’s poorest.
  16. (1999). IMS Health Global Insight Reports.
  17. (1998). In: Medicines and the New Economic Environment (eds F Lobo & G Velasquez). Biblioteca Civitas Economia y Empresa,
  18. (1999). Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts.
  19. (1994). New drug developments in the United States from 1963 to
  20. (1999). Orphan drugs: the United States experience.
  21. (2001). Patents in a genetic age.
  22. (1999). Political economy of technology transfer.
  23. (1996). Recherche et de ´ veloppement pharmaceutiques en matie`re de maladies transmissibles dans la zone intertropicale.
  24. Report prepared for the Directorate General Enterprise of the European Commission.
  25. (1998). The normalisation of the international market for pharmaceuticals: future impacts in emerging markets.
  26. (2001). Top Performing Industries.
  27. (1999). Updating the Cost of a New Chemical Entity. Office of Health Economics,
  28. (1999). World Health Organization

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.